Introduction ▼
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Conclusion:
High circulating endoglin correlated with a poor outcome for BA. Plasma endoglin can be utilized as a potential biomarker refl ecting the severity of ongoing liver injury and biliary obstruction in BA patients after Kasai procedure.
Downloaded by: Chulalongkorn University. Copyrighted material. CD105, is a 180 kDa homodimeric transmembrane glycoprotein of the receptor complex for fi brogenic cytokines TGF-β 1 and TGF-β 3 [25] . Endoglin is highly expressed on vascular endothelial cells, monocytes, and erythroid precursors [13] . Several studies have implicated endoglin as playing a role in the development of fi brosis in systemic sclerosis, glomerulosclerosis and hepatic cirrhosis [6, 8, 9] . Although circulating levels of various growth factors and cytokines have been extensively studied in patients with BA, published data on serum endoglin levels from various clinical stages of BA are not currently available [15 -18, 23, 24] . To our knowledge, this study is the fi rst to demonstrate the important role of circulating endoglin in postoperative BA. We postulated that circulating endoglin would be more elevated in BA patients compared to healthy controls, and to prove this hypothesis, we examined circulating endoglin levels in BA patients and healthy controls. Thus, the aim of the current study was to investigate the circulating concentrations of endoglin collected from postoperative BA patients and determine the relationship between plasma endoglin and outcome parameters of BA patients after Kasai operation.
Patients and Methods

▼ Study population
Fifty-fi ve pediatric patients with BA (22 boys and 33 girls; mean age = 8.0 ± 0.5 years) who had undergone hepatic portojejunostomy with Roux-en-Y reconstruction (Kasai procedure) and never received a liver transplantation were enrolled in the study. The control group comprised 14 healthy children (6 boys and 8 girls; mean age = 8.1 ± 0.3 years) who attended the Well Baby Clinic at King Chulalongkorn Memorial Hospital for vaccination. The children in the control group had normal fi ndings and no previous medical illness. During blood collection, none of the BA patients displayed any signs and symptoms of fever or ascending cholangitis or clotting disorders.
To correlate biochemical parameters with clinical outcomes of BA patients, patients were divided into two groups according to serum total bilirubin (TB) and serum alanine aminotransferase (ALT) levels. Based on their jaundice status, BA children were divided into a jaundice-free group (TB < 34.2 μ mol / L, n = 33) and a persistent jaundice group (TB ≥ 34.2 μ mol / L, n = 22). Further classifi cation was done based on serum ALT status, i. e., patients were grouped into a normal ALT group (ALT < 45 IU / L, n = 17) and a high ALT group (ALT ≥ 45 IU / L, n = 38). Subsequently, portal hypertension (PH) was validated by the presence of ascites and / or esophageal varices as diagnosed by endoscopic screening. Fifteen of the 33 BA children without jaundice and 20 of 22 children with persistent jaundice had evidence of portal hypertension. The study protocol was approved by the Institutional Ethical Review Board of the Faculty of Medicine, Chulalongkorn University. The present study was conducted in accordance with the guidelines of the Declaration of Helsinki. All parents of children were informed of the purpose of this study and of any interventions involved in this study. Written informed consent was obtained prior to the children participating in this study.
Laboratory methods
Samples of peripheral venous blood were collected from each patient and healthy controls, centrifuged and then stored at − 80 ° C until analysis. Plasma endoglin concentrations were measured using a commercially available enzyme-linked immunosorbant assay (ELISA) kit (Quantikine high sensitivity human endoglin / CD105 immunoassay, R & D Systems, Minneapolis, MN, USA) following the manufacturer ' s recommendations. Briefl y, standards of recombinant human endoglin and plasma samples were added to microtiter plates pre-coated with mouse monoclonal antibody against human endoglin and incubated for 2 h at room temperature. The wells were then washed four times with washing buff er and incubated for 2 h at room temperature with a horseradish peroxidase-conjugated monoclonal antibody against endoglin. After four washes, substrate solution was added to each well, and the plate was incubated in the dark for 30 min at room temperature. Finally, the reaction was stopped with the stop solution, and absorbance was then measured at 450 nm using an automated microplate reader. Recombinant human endoglin was used to generate a linear standard calibration curve (range 0 -10 ng / mL). The manufacturer reported precision was 2.8 -3.2 % intra-assay, and 6.3 -6.7 % inter-assay. In addition, liver function tests including serum albumin, total bilirubin (TB), direct bilirubin (DB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) were done using an automated chemical analyzer (Hitachi 911) at the central laboratory of our hospital.
Statistical analysis
Statistical analysis was performed using the statistical package for social sciences (SPSS) software, version 16 Table 1 . BA patients with persistent jaundice had significantly lower albumin levels than those without jaundice, while serum levels of AST, ALT, and ALP were highly elevated in the BA patients with jaundice compared to those without jaundice.
As shown in • ▶ Fig. 1 , circulating endoglin values measured in the healthy control group, total BA group, jaundice-free group, and jaundice group were 6.5 ± 0.4, 7.8 ± 0.4, 6.9 ± 0.3, and 9.2 ± 0.8 ng / mL, respectively. BA patients had signifi cantly higher plasma endoglin concentrations than healthy controls ( p = 0.02).
In BA patients, plasma endoglin levels of patients with persistent jaundice were signifi cantly elevated compared to those of patients without jaundice ( p = 0.006). There was no signifi cant diff erence in plasma endoglin levels between the jaundice-free group and controls ( • ▶ Fig. 1 ).
Subsequently, BA patients were re-evaluated with regard to serum ALT levels, as demonstrated in • ▶ Table 2 . A subgroup analysis of BA children revealed that patients with high ALT levels had more elevated plasma endoglin levels than patients with normal ALT levels and healthy controls (8.5 ± 0.5 vs. 6 .3 ± 0.5 vs.
6.5 ± 0.4 ng / mL, respectively; p = 0.003) ( • ▶ Fig. 2 ). In addition, BA patients with portal hypertension (PH) had signifi cantly higher levels of plasma endoglin compared to those without PH (8.8 ± 0.6 vs. 6 .1 ± 0.3 ng / mL; p = 0.001), as displayed in • ▶ Fig. 3 . Particularly in BA patients without jaundice, plasma endoglin levels 
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No jaundice n=33 Jaundice n=22 Fig. 1 Correlation of plasma endoglin levels in biliary atresia patients with total bilirubin levels and controls. Data are expressed as mean ± SEM. Furthermore, a previous investigation reported that elevated intrahepatic and circulating endoglin was associated with progressive hepatic fi brosis in chronic hepatitis C virus infection [6] . However, there have been no published studies on the role of endoglin in biliary atresia and on the relationship between endoglin and the clinical outcome of BA. The current study revealed that circulating endoglin levels in BA patients were signifi cantly higher than those in healthy controls.
In the BA patients, plasma endoglin levels were more elevated in BA patients with persistent jaundice than in those without jaundice. Further analysis demonstrated that BA patients with high ALT levels had increased concentrations of plasma endoglin compared to those with normal ALT. Elevated plasma endoglin was positively correlated with serum ALT and serum GGT in postoperative BA patients. Serum ALT routinely serves as a specifi c biochemical parameter of liver dysfunction refl ecting hepatocellular damage. In addition, serum GGT is likely to be an indicator for the severity of biliary obstruction. Therefore, these fi ndings suggest that plasma endoglin can be utilized as a prognostic biomarker for ongoing liver injury and biliary obstruction in postoperative BA.
To our knowledge, the present study is the fi rst to show that circulating endoglin is elevated in BA patients compared with healthy controls, and that endoglin concentration is associated with a therapeutic outcome (jaundice status, hepatic dysfunction, and portal hypertension) in BA. Recently, an increase of endoglin expression in circulation and / or liver tissue has been documented for a number of liver diseases, including chronic hepatitis, liver cirrhosis and hepatocellular carcinoma [6, 26, 27] .
In accordance with the fi ndings of this study, Clemente et al. demonstrated an elevation of circulating endoglin with advancing chronic hepatitis [6] . Furthermore, Yagmur et al. revealed that circulating endoglin increased signifi cantly in patients with cirrhosis and hepatocellular carcinoma and was correlated with the severity of hepatic damage [26] . In addition, the expression of intrahepatic endoglin has been demonstrated in bile ductligated rats as described by D í az-Gil et al. [10] . More prospective studies on hepatic endoglin expression are required to elucidate the mechanisms of endoglin in BA.
It is interesting to point out that the results of this study are consistent with our recent publication showing that serum tissue inhibitors of metalloproteinase-1, stem cell factor, basic fi broblast growth factor, and transforming growth factor-β 1 were more pronounced in BA children than in healthy controls [16 -18, 24] . These cytokines are signifi cantly associated with outcomes in postoperative BA and have been implicated in progressive hepatic fi brosis. Endoglin levels, like those of previous cytokines, were found to be correlated to the progression of liver dysfunction and portal hypertension. Future research on additional cytokines and growth factors may help identify more pieces of the infl ammatory jigsaw of BA; nevertheless, the challenge remains to piece them together to create a logical solid hypothesis regarding their precise role.
In the light of these considerations, various possible mechanisms could be responsible for the elevation of circulating endoglin in BA patients. Firstly, production of endoglin in the damaged liver may result in high levels of plasma endoglin. Secondly, elevated endoglin concentrations could be ascribed to an imbalance between endoglin production and endoglin clearance. In advanced BA stages, reduced endoglin clearance may possibly contribute to increased circulating endoglin levels. Moreover, because other organs apart from the liver can synthesize and secrete endoglin, the major sources of elevated plasma endoglin in the present study could be extrahepatic organs. Additional investigation will be needed to clarify this observation. It should be mentioned, however, that our study has some limitations. The sample size of patients enrolled in this study was small. A further study with a random sample from a larger population will be needed to draw a more defi nite conclusion. In addition, incomplete assessment of potential confounders such needs as age, gender, and medical comorbidities needs to be taken into account. As this study was designed as a crosssectional study, a defi nite cause and eff ect relationship cannot be concluded. However, with the supporting evidence from other studies based on the role of endoglin in liver cirrhosis and hepatic fi brosis [6, 10, 26, 27] , it is likely that the elevated plasma endoglin levels found in postoperative BA patients may be involved in the pathophysiology of hepatocellular injury and the development of portal hypertension.
To summarize, the current study demonstrated that BA patients had signifi cantly elevated circulating levels of endoglin compared with healthy controls. Plasma endoglin was more pronounced in BA children with persistent jaundice compared to those without jaundice. Additionally, plasma endoglin in BA patients with high ALT was signifi cantly elevated compared to those with normal ALT. Further analysis showed that BA patients with PH had markedly higher plasma endoglin levels than those without PH. These fi ndings suggest that high levels of circulating endoglin are associated with hepatic injury and hence refl ect the magnitude of liver dysfunction in BA. There was a positive correlation between plasma endoglin, serum ALT, and serum GGT. Endoglin measurement may be used as a potential biomarker for progression to hepatic dysfunction and could be predictive of prognosis with respect to the development of PH during the follow-up of postoperative BA patients.
